News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Impulse Dynamics secures $30m for novel heart implant Chronic heart failure (CHF) device specialist Impulse Dynamics has secured £30 million in financing.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.